Results 251 to 260 of about 27,407 (265)

SGLT2 inhibitors and cardiovascular outcomes

Drug and Therapeutics Bulletin, 2017
openaire   +2 more sources

Dapagliflozin, an SGLT2 inhibitor, for diabetes

The Lancet, 2010
Markolf, Hanefeld, Thomas, Forst
openaire   +2 more sources

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

New England Journal of Medicine, 2017
Michael Fralick, Elisabetta Patorno, Fralick Michael   +2 more
exaly  

A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery

AACE Clinical Case Reports, 2021
exaly  

Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design

Bioorganic and Medicinal Chemistry Letters, 2016
Jie Shen, Peng Wang, Xuefeng Cao
exaly  

The expanding résumé of SGLT2 inhibitors

The Lancet Diabetes & Endocrinology, 2019
openaire   +2 more sources

SGLT2 Inhibitors and Iron

JACC: Heart Failure, 2023
openaire   +1 more source

SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis

Clinical Therapeutics, 2016
Ronald M Goldenberg, Subodh Verma, Jean-François Yale   +2 more
exaly  

SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation

Cell Metabolism
Jingwen Qi
exaly  

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

British Journal of Pharmacology, 2011
exaly